Pyc Therapeutics
Clinical trials sponsored by Pyc Therapeutics, explained in plain language.
-
New eye drug hopes to slow inherited blindness
Disease control Recruiting nowThis early-stage study tests a new medicine called PYC-001, given as an injection into the eye, for people with a rare genetic eye disease (autosomal dominant optic atrophy) caused by a change in the OPA1 gene. The main goal is to check the safety of different doses and schedules…
Phase: PHASE1, PHASE2 • Sponsor: PYC Therapeutics • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
New drug targets genetic kidney disease in first human trial
Disease control Recruiting nowThis early-stage study tests a new drug called PYC-003 in healthy people and those with a genetic kidney disease called ADPKD. The main goal is to check if the drug is safe and how the body processes it. If successful, this drug could help slow down kidney damage in people with A…
Phase: PHASE1 • Sponsor: PYC Therapeutics • Aim: Disease control
Last updated Jun 11, 2026 12:10 UTC